134 related articles for article (PubMed ID: 19437115)
1. Association of interleukin-10 gene variation with breast cancer prognosis.
Gerger A; Renner W; Langsenlehner T; Hofmann G; Knechtel G; Szkandera J; Samonigg H; Krippl P; Langsenlehner U
Breast Cancer Res Treat; 2010 Feb; 119(3):701-5. PubMed ID: 19437115
[TBL] [Abstract][Full Text] [Related]
2. Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer.
Knechtel G; Hofmann G; Gerger A; Renner W; Langsenlehner T; Szkandera J; Wolf G; Samonigg H; Krippl P; Langsenlehner U
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1813-9. PubMed ID: 20204402
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation in pro-inflammatory cytokines (interleukin-1beta, interleukin-1alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma.
Snoussi K; Strosberg AD; Bouaouina N; Ben Ahmed S; Chouchane L
Eur Cytokine Netw; 2005 Dec; 16(4):253-60. PubMed ID: 16464738
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
6. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.
Qian B; Katsaros D; Lu L; Preti M; Durando A; Arisio R; Mu L; Yu H
Breast Cancer Res Treat; 2009 Sep; 117(1):131-40. PubMed ID: 18932017
[TBL] [Abstract][Full Text] [Related]
7. Association between polymorphisms of the BRCA2 gene and clinical parameters in breast cancer.
Krupa R; Sliwinski T; Morawiec Z; Pawlowska E; Zadrozny M; Blasiak J
Exp Oncol; 2009 Dec; 31(4):250-1. PubMed ID: 20010525
[TBL] [Abstract][Full Text] [Related]
8. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
9. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO
Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877
[TBL] [Abstract][Full Text] [Related]
10. Association of BRCA2 polymorphism at codon 784 (Met/Val) with breast cancer risk and prognosis.
Ishitobi M; Miyoshi Y; Ando A; Hasegawa S; Egawa C; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2003 Apr; 9(4):1376-80. PubMed ID: 12684407
[TBL] [Abstract][Full Text] [Related]
11. Association of cyclin D1 genotype with breast cancer risk and survival.
Shu XO; Moore DB; Cai Q; Cheng J; Wen W; Pierce L; Cai H; Gao YT; Zheng W
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):91-7. PubMed ID: 15668481
[TBL] [Abstract][Full Text] [Related]
12. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study.
Joensuu H; Isola J; Lundin M; Salminen T; Holli K; Kataja V; Pylkkänen L; Turpeenniemi-Hujanen T; von Smitten K; Lundin J
Clin Cancer Res; 2003 Mar; 9(3):923-30. PubMed ID: 12631589
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer.
Choi JY; Lee KM; Park SK; Noh DY; Ahn SH; Chung HW; Han W; Kim JS; Shin SG; Jang IJ; Yoo KY; Hirvonen A; Kang D
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1090-5. PubMed ID: 15894657
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
[TBL] [Abstract][Full Text] [Related]
15. Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study.
Deming SL; Ren Z; Wen W; Shu XO; Cai Q; Gao YT; Zheng W
Breast Cancer Res Treat; 2007 Sep; 104(3):309-19. PubMed ID: 17063263
[TBL] [Abstract][Full Text] [Related]
16. A 10-year follow-up of triple-negative breast cancer patients in Taiwan.
Lin C; Chien SY; Kuo SJ; Chen LS; Chen ST; Lai HW; Chang TW; Chen DR
Jpn J Clin Oncol; 2012 Mar; 42(3):161-7. PubMed ID: 22287721
[TBL] [Abstract][Full Text] [Related]
17. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
18. The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk.
Langsenlehner U; Yazdani-Biuki B; Eder T; Renner W; Wascher TC; Paulweber B; Weitzer W; Samonigg H; Krippl P
Clin Cancer Res; 2006 Feb; 12(4):1392-4. PubMed ID: 16489098
[TBL] [Abstract][Full Text] [Related]
19. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
[TBL] [Abstract][Full Text] [Related]
20. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]